[Selective cyclooxygenase-2 (COX-2) inhibitors. Beliefs, reality and hope].
Brune
K
K
Institut für Experimentelle und Klinische Pharmakologie und Toxikologie der Universität Erlangen-Nürnberg.
D000210:Acute-Phase Reaction / Q000188:drug therapy* / Q000201:enzymology; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D051546:Cyclooxygenase 2; D004790:Enzyme Induction / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007527:Isoenzymes / Q000502:physiology*; D008565:Membrane Proteins; D011451:Prostaglandin-Endoperoxide Synthases / Q000502:physiology*; D018746:Systemic Inflammatory Response Syndrome / Q000188:drug therapy* / Q000201:enzymology; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D004791:Enzyme Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases